Microfluidic-assisted nanoprecipitation of biodegradable nanoparticles composed of PTMC/PCL (co)polymers, tannic acid and doxorubicin for cancer treatment

This study was aimed towards the development of a novel microfluidic approach for the preparation of (co) polymeric and hybrid nanoparticles (NPs) composed of (co)polymers/tannic acid (TA) in the microfluidic flowfocusing glass-capillary device. The MiliQ water was used as water phase, whereas the organic phase was composed of poly(?-caprolactone) (PCL) and poly(trimethylene carbonate) (PTMC) homopolymers and (co) polymers with different proportion of comonomers which were prepared via enzymatic polymerization that allows avoiding the usage of potentially toxic catalyst. To prepare hybrid NPs, TA was additionally added to the organic phase. Subsequently, as a result of mixing between these distinct phases in microfluidic channels, the nanoprecipitation in the form of spherical NPs occurs. The size of NPs was tuned over the range of 140?230 nm by controlling phase flow rates and the composition of NPs. Moreover, the release studies of the encapsulated anticancer drug doxorubicin (DOX) demonstrated that the drug release is greatly influenced by the (co)polymers composition, their molecular weight, NPs size, and the presence of TA. The antitumor activities of the (co) polymeric and hybrid NPs toward breast cancer cells (MCF-7) were tested in vitro. Among all tested formulation, the NPs composed of PCL/TA most efficiently inhibit the cell proliferation of MCF-7 cells, most importantly, their efficiency was higher than free DOX. The proposed strategy may provide an efficient alternative for the construction of nanocarriers with great potential in anticancer therapy.

Automated summary

This study developed a novel microfluidic approach for preparing (co)polymeric and hybrid nanoparticles, which showed great potential in drug release and inhibition of breast cancer cells. The composition of PCL/TA NPs demonstrated the most efficient antitumor activity among all formulations, surpassing the efficacy of free DOX.